Residential Cleaning of Indoor Air to Protect COPD Patients

NACompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

March 26, 2021

Study Completion Date

March 26, 2021

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DEVICE

HEPAirX air filter

It is a trademarked, patented (U.S. Patent # 7,802,443), U.S. FDA approved Class II medical re-circulating air cleaner, built by Air Innovations, Inc. (North Syracuse, NY) to provide improved indoor air quality in the bedrooms of asthmatic children. Units to be used in the proposed study have a 99.97% efficient filter for particles 0.3 µm in size. The device provides a clean air delivery rate (CADR) of 9 per hour with 1.8 of them being outdoor air.

DEVICE

control air filter

A placebo mode was added to the HEPAirX to provide only recirculation (without filtration or ventilation using outdoor air) and temperature control of the room air. The placebo filter is made of metal.

Trial Locations (1)

14642

University of Rochester Medical Center, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER

NCT03750292 - Residential Cleaning of Indoor Air to Protect COPD Patients | Biotech Hunter | Biotech Hunter